CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer

• We investigate CDX2 expression with both immunohistochemistry and RT-qPCR.
• Low CDX2 expression is associated with right-sided tumors, poor differentiation grade and MMR-deficiency.
• There is a high concordance between the results from immunohistochemistry and RT-qPCR.
• CDX2 expression was not significantly associated with recurrence risk.

BackgroundHomeobox genes are often deregulated in cancer and can have both oncogenic and tumor-suppressing potential. The Caudal-related homeobox transcription factor 2 (CDX2) is an intestine-specific transcription factor. CDX2 has been implicated in differentiation, proliferation, cell adhesion, and migration. In this study, we investigated CDX2 mRNA and protein expression in relation to the clinicopathological characteristics of colon cancer, including mismatch repair status and recurrence risk.MethodsTumor samples were obtained from colon cancer patients. Biopsies from tumor tissue and normal adjacent tissue were fixed in liquid nitrogen for RNA extraction or in formalin and paraffin embedded (FFPE) for immunohistochemical staining. CDX2 mRNA expression was evaluated by RT-qPCR. FFPE sections were stained for MLH1, MSH2, MSH6, PMS2, and CDX2.ResultsA total of 191 patient samples were included in the study and analyzed by immunohistochemistry. Of these samples, 97 were further evaluated by RT-qPCR. There was no significant difference in CDX2 mRNA expression between tumor and normal tissues. CDX2 mRNA expression was significantly lower in right-sided tumors (p < 0.05), poorly differentiated tumors (p < 0.05), and MMR-deficient tumors (p < 0.05). Similarly, CDX2 protein expression was more often low or absent in right-sided tumors (p < 0.01), poorly differentiated tumors (p < 0.001), and MMR-deficient tumors (p < 0.001). Low CDX2 protein or mRNA expression was not associated with recurrence risk.ConclusionWe found that CDX2 downregulation is associated with MMR deficiency, right-sided tumors, and poor differentiation at both the mRNA and protein level. Whether CDX2 plays an active role in tumor progression in MSI/MMR-deficient tumors remains to be elucidated.